Flerie invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges.
Location: Sweden, Stockholm
Employees: 1-10
Founded date: 2011
Investment Type: Venture Capital
Portfolio 32
| Date | Name | Website | Total Raised | Location |
| 09.02.2023 | Prokarium | prokarium.com | $35.62M | United Kin... |
| 11.10.2022 | Alder Ther... | aldertx.com | - | Sweden, So... |
| 08.09.2022 | AnaCardio | anacardio.com | $22.56M | Sweden, So... |
| 08.09.2022 | NorthX Bio... | nxbio.com | - | Sweden, Tu... |
| 20.08.2022 | Vitara Bio... | vitara.com | - | United Sta... |
| 20.08.2022 | Xintela AB | xintela.se | $939.79K | Sweden, Lu... |
| 08.05.2022 | A3P Biomed... | a3p.com | - | - |
| 25.04.2022 | Bohus BioT... | bohusbiotech.com | - | - |
| 06.04.2022 | XNK Therap... | xnktherapeutics.com | - | Sweden, Hu... |
| 06.04.2022 | Geneos The... | geneostx.com | $10M | United Sta... |
Show more
Mentions in press and media 10
| Date | Title | Description |
| 10.06.2024 | Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024 | Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024 Mon, Jun 10, 2024 09:55 CET Report this content June 10, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceutical... |
| 07.06.2024 | InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie | InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie Fri, Jun 07, 2024 16:30 CET Report this content June 7, 2024 - InDex Pharmaceuticals Hold... |
| 04.06.2024 | InDex Pharmaceuticals publishes NAV for Flerie as of May 31, 2024 | InDex Pharmaceuticals publishes NAV for Flerie as of May 31, 2024 Tue, Jun 04, 2024 08:55 CET Report this content June 4, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or the "Company") entered ... |
| 03.06.2024 | Michael Grissinger appointed as new Chairman of AnaCardio | Michael Grissinger appointed as new Chairman of AnaCardio Mon, Jun 03, 2024 08:00 CET Report this content PRESS RELEASE Stockholm, Sweden, June 3, 2024 AnaCardio, a Swedish clinical-stage biopharmaceutical company focusing on developing nov... |
| 27.05.2024 | InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie | InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie Mon, May 27, 2024 17:15 CET Report this content May 27, 2024 - InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" or... |
| 20.05.2024 | InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie | InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie Mon, May 20, 2024 21:00 CET Report this content 20 May 2024 – InDex Pharmaceuticals Holding AB (publ) ("InDex Pharmaceuticals" o... |
| 07.09.2022 | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure | AnaCardio raises SEK 150 million to advance drug candidate AC01 in heart failure Wed, Sep 07, 2022 08:00 CET Report this content STOCKHOLM, SWEDEN - 7 September 2022: AnaCardio announced today the completion of a SEK 150 M Series A financin... |
| 29.03.2022 | XNK Therapeutics raises SEK 132 million to accelerate growth | XNK Therapeutics raises SEK 132 million to accelerate growth Tue, Mar 29, 2022 08:05 CET Report this content XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, to existing and new investors, l... |
| 07.03.2022 | Tencent backs Cambridge-based startup in $67 million funding to address opportunities in biomedicine | Cambridge-based player in the field of microbiome-based therapeutics, biomarkers and targets, Microbiotica has raised £50 million ($67 million) funding. The Series B round was co-led by Flerie Invest and Tencent with participation from new ... |
| - | Tencent backs Cambridge-based startup in $67 million funding to address opportunities in biomedicine | Cambridge-based player in the field of microbiome-based therapeutics, biomarkers and targets, Microbiotica has raised £50 million ($67 million) funding. The Series B round was co-led by Flerie Invest and Tencent with participation from new ... |